4//SEC Filing
Gould Robert J 4
Accession 0000899243-22-021530
CIK 0001680581other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 7:33 PM ET
Size
9.7 KB
Accession
0000899243-22-021530
Insider Transaction Report
Form 4
Gould Robert J
Director
Transactions
- Exercise/Conversion
Common Stock
2022-06-07$7.84/sh+71,435$560,050→ 578,065 total - Sale
Common Stock
2022-06-07$8.09/sh−71,435$577,895→ 506,630 total - Exercise/Conversion
Stock Option (right to buy)
2022-06-07−71,435→ 86,523 totalExercise: $7.84Exp: 2022-06-30→ Common Stock (71,435 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.35, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.
Documents
Issuer
Fulcrum Therapeutics, Inc.
CIK 0001680581
Entity typeother
Related Parties
1- filerCIK 0001577034
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 7:33 PM ET
- Size
- 9.7 KB